Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) lacks effective therapies, highlighting miRNAs as potential therapeutic targets owing to their biological functions and analytical accessibility. This study aimed to investigate the role of miR-145-5p in CRSwNP. Serum samples and inferior turbinate mucosa tissues were collected from 175 CRSwNP patients and 90 nasal septum deviation (NSD) subjects. qRT-PCR measured miR-145-5p expression in serum and tissue samples, and CD40 expression in tissues. ROC curve evaluated the diagnostic efficacy. Associations with disease severity and eosinophilic CRSwNP (ECRSwNP) risk were analyzed through correlation and logistic regression analysis. Dual-luciferase assay confirmed miR-145-5p targeting CD40. LPS-induced inflammation in human nasal epithelial cells (hNEpCs) assessed the miR-145-5p/CD40 axis's impact on IL-6, IL-1β, and TNF-α levels. Tissue and serum miR-145-5p effectively diagnosed CRSwNP. Reduced miR-145-5p correlated with disease severity and was an independent ECRSwNP risk factor. In LPS-stimulated hNEpCs, miR-145-5p overexpression suppressed IL-6, IL-1β, and TNF-α. CD40 expression inversely correlated with miR-145-5p and amplified inflammatory responses mitigated by miR-145-5p overexpression. MiR-145-5p, serving as a diagnostic biomarker for CRSwNP, was negatively correlated with disease severity. MiR-145-5p overexpression attenuated inflammation in hNEpCs by targeting CD40, thereby involving itself in the progression of CRSwNP, suggesting therapeutic potential for CRSwNP management.

Download full-text PDF

Source
http://dx.doi.org/10.1111/apm.70045DOI Listing

Publication Analysis

Top Keywords

targeting cd40
12
disease severity
12
mir-145-5p overexpression
12
mir-145-5p
11
chronic rhinosinusitis
8
rhinosinusitis nasal
8
crswnp
8
cd40 expression
8
ecrswnp risk
8
il-6 il-1β
8

Similar Publications

The effect of CD40 agonist antibody therapy on the pancreatic cancer microenvironment.

Naunyn Schmiedebergs Arch Pharmacol

September 2025

Department of Gastroenterology, Jinhua Central Hospital, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, Zhejiang, China.

The fourth leading cause of cancer-related fatalities in the USA is pancreatic ductal adenocarcinoma (PDAC), a particularly deadly illness that is resistant to immunotherapy. One of the Main Obstacles in cancer research is developing better treatments for PDAC, which has the lowest 5-year survival rate of any malignancy. Anti-CTLA-4, anti-PD-L1, and anti-PD-1 immune checkpoint blockade medications also have poor results in these patients, which may indicate the presence of other immunosuppressive mechanisms in the pancreatic tumor microenvironment (TME).

View Article and Find Full Text PDF

Despite recent progress within the field of immuno-oncology, immune suppression in the tumor microenvironment, defective antigen presentation, and low levels of tumor-specific T cells are key limitations of current cancer immunotherapies. CD40-targeting immunotherapies hold promises for addressing these limitations across solid tumors. Here, we describe ATOR-4066, a bispecific antibody that targets CD40 and CEACAM5 developed for immunotherapy of cancer using the Neo-X-Prime platform.

View Article and Find Full Text PDF

Multi-omic analysis reveals a key BCAT1 role in mTOR activation by B-cell receptor and TLR9.

J Clin Invest

September 2025

Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, United States of America.

B-lymphocytes play major adaptive immune roles, producing antibody and driving T-cell responses. However, how immunometabolism networks support B-cell activation and differentiation in response to distinct receptor stimuli remains incompletely understood. To gain insights, we systematically investigated acute primary human B-cell transcriptional, translational and metabolomic responses to B-cell receptor (BCR), Toll-like receptor 9 (TLR9), CD40-ligand (CD40L), interleukin-4 (IL4) or combinations thereof.

View Article and Find Full Text PDF

Recombinant spider silk functionalized with a CD40 agonist shows improved capability to activate human B cells in vitro - A novel module for cancer immunotherapy.

Int J Biol Macromol

September 2025

Department of Protein Science, Division of Protein Technology, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, AlbaNova University Center, Stockholm, Sweden. Electronic address:

This paper presents the generation and evaluation of a novel potential drug delivery platform for biologics, based on recombinant spider silk. Targeting CD40 for activation of antigen presenting cells, in order to overcome tumor induced T cell tolerance, have shown promising results in cell and animal models. However, further trials have gained limited results due to severe side reactions.

View Article and Find Full Text PDF

Background And Objective: CD68 plays a crucial role in promoting phagocytosis. However, its expression level, prognostic value and the correlations with tumor-infiltrating immune cells (TIICs) or common tumor immune checkpoints (TICs) in human digestive system cancers (DSC) remain poorly understood. This study aims to investigate the expression levels, prognostic significance, and clinical implications of CD68, as well as its correlations with six TIICs and four common TICs in DSC.

View Article and Find Full Text PDF